Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Cytotherapy, 2(16), p. 149-159

DOI: 10.1016/j.jcyt.2013.11.010

Links

Tools

Export citation

Search in Google Scholar

The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care

Journal article published in 2014 by Francesco Saglio ORCID, Patrick J. Hanley, Catherine M. Bollard
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Adoptive immunotherapy—in particulary T cell therapy—has recently emerged as a useful strategy with the potential to overcome many of the limitations of antiviral drugs for the treatment of viral complications after hematopietic stem cell transplantation (HSCT). In this review we briefly summarize the current methods for virus- specific T cell isolation or selection and we report results from clinical trials employing these techniques, focusing specifically on the strategies aimed to broaden the application of this technology.